Also trades as: NRSN (NASDAQ) · $vol 0M
NRSNW NASDAQ
NeuroSense Therapeutics Ltd.
1W: -55.6%
1M: +1.3%
3M: -72.4%
YTD: -86.7%
1Y: -93.7%
3Y: -88.2%
$0.04
-0.01 (-11.11%)
Weekly Expected Move ±85.5%
$-0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.0M
52W Range0.0391-0.5445
Volume2,288
Avg Volume1,536
Beta1.60
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAlon Ben-Noon
Employees16
SectorHealthcare
IndustryBiotechnology
IPO Date2021-12-09
Websiteneurosense-tx.com
Building B
Herzliya, TA 4672562
IL
Herzliya, TA 4672562
IL
972 9 953 1142
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.
Latest News
NeuroSense Provides Update on Nasdaq Listing Compliance
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Stock Has Consensus Price Target of $170.00
FY2026 Earnings Forecast for NRSN Issued By HC Wainwright
NeuroSense Issues CEO Letter to Shareholders
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Recommendation of “Moderate Buy” by Analysts
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Eisenberg Or | A-Award | 200,000 | — | 2026-03-26 |
| Russek-Blum Niva | A-Award | 200,000 | — | 2026-03-26 |
| Binder Hagit | A-Award | 200,000 | — | 2026-03-26 |
| Eisenberg Or | 0 | — | 2026-03-18 | |
| Eisenberg Or | 0 | — | 2026-03-18 |